Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo

Journal of Clinical Psychiatry

Volumn 62, Issue 11, 2001, Pages 869-877

  Entsuah, A R ^a   Huang, H ^a   Thase, M E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MOOD; POPULATION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION;

EID: 0035196264     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n1106     Document Type: Article

References (48)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
2. Cross-national epidemiology of major depression and bipolar disorder
3. Implications of failing to achieve successful longterm maintenance treatment of recurrent unipolar major depression
4. The clinical course of unipolar major depressive disorders
5. Depression comorbid with anxiety: Results from the WHO study on psychological disorders in primary health care
6. On behalf of collaborating investigators. Conclusions
7. The underrecognition and undertreatment of depression: What is the breadth and depth of the problem?
8. Evidence-based health policy: Lessons from the Global Burden of Disease study
9. Depression in women: Implications for health care research
10. The changing rate of major depression cross-national comparisons
11. Natural history of Diagnostic Interview Schedule/DSM-IV major depression: The Baltimore Epidemiologic Catchment Area follow-up
12. Reversed symptoms of depression: A community study of Ontario
13. Hypothalamic- pituitary-adrenocortical activity and response to cognitive behavior therapy in unmedicated, hospitalized depressed patients
14. Gonadal hormones, reproductive age, and women with depression
15. Prevalence rates of major depressive disorders: The effects of varying the diagnostic criteria in an older primary care population
16. Profile of depressive symptoms in younger and older medical inpatients with major depression
17. Incidence of depression in long-term care settings
18. Follow-up study of depression in the elderly: Clinical and SPECT data
19. Brain changes in geriatric depression
20. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication
21. Clinical significance of reversed vegetative subtypes of recurrent major depression
22. Gender differences in treatment response to sertraline versus imipramine in chronic depression
23. Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients
24. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: A placebo-controlled, double-blind study
25. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia
26. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: Meta-regression analysis
27. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
28. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: A meta-analysis
29. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression
30. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression
31. Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers
32. Pharmacokinetics of once-daily venlafaxine extended release in healthy volunteers
33. A double-blind comparison of venlafaxine and fluoxetme in patients hospitalized for major depression and melancholia
34. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients
35. A double-blind randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
36. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety
37. Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study
38. Once-daily venlafaxine XR versus paroxetine in outpatients with major depression
39. A rating scale for depression
40. A new depression scale designed to be sensitive to change
41. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence
42. Gender differences in response to lithium treatment
43. Practice guideline for major depressive disorder in adults
44. How should efficacy be evaluated in randomized clinical trials of treatments for depression?